Related references
Note: Only part of the references are listed.An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?
Nathan Cherny
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada
Daniel E. Meyers et al.
JAMA INTERNAL MEDICINE (2021)
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
Kathleen L. Miller et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'
N. Groessmann et al.
ESMO OPEN (2021)
Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs
Ashlyn Pinto et al.
VALUE IN HEALTH (2020)
Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
Run-Cong Nie et al.
BMC CANCER (2020)
Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
Takehiro Hirai et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
The cost of cancer in Europe 2018
Thomas Hofmarcher et al.
EUROPEAN JOURNAL OF CANCER (2020)
Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015
Nicole Groessmann et al.
EUROPEAN JOURNAL OF CANCER (2020)
Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
Talal Hilal et al.
JAMA INTERNAL MEDICINE (2020)
Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015
N. Groessmann et al.
EUROPEAN JOURNAL OF CANCER (2019)
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
Talal Hilal et al.
JAMA ONCOLOGY (2019)
Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada
Fernanda Naomi Inagaki Nagase et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
Alyson Haslam et al.
EUROPEAN JOURNAL OF CANCER (2019)
Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions
Susanna M. Wallerstedt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017
Chris Skedgel et al.
PHARMACOECONOMICS (2018)
Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia
Deme J. Karikios et al.
INTERNAL MEDICINE JOURNAL (2017)
Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview
Nerys Woolacott et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2017)
The high price of anticancer drugs: origins, implications, barriers, solutions
Vinay Prasad et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Do cancer drugs improve survival or quality of life? You don't need to know, according to our broken regulatory system
Vinay Prasad
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Do cancer drugs improve survival or quality of life? You don't need to know, according to our broken regulatory system
Vinay Prasad
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Robert Kemp et al.
BMC MEDICINE (2017)
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
S. Michiels et al.
ANNALS OF ONCOLOGY (2016)
Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014
P. Savage et al.
BRITISH JOURNAL OF CANCER (2015)
Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness
Mikael Svensson et al.
PHARMACOECONOMICS (2015)
A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results
Tessa Kennedy-Martin et al.
TRIALS (2015)
Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland? A Retrospective Analysis 2006-2013
Mata Charokopou et al.
VALUE IN HEALTH (2015)
Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
Michael Wonder et al.
VALUE IN HEALTH (2015)
Drugs, cancer and end-of-life care: A case study of pharmaceuticalization?
Courtney Davis
SOCIAL SCIENCE & MEDICINE (2015)
The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2015)
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
Chul Kim et al.
JAMA INTERNAL MEDICINE (2015)
THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS
Helen Dakin et al.
HEALTH ECONOMICS (2015)
Pricing in the Market for Anticancer Drugs
David H. Howard et al.
JOURNAL OF ECONOMIC PERSPECTIVES (2015)
Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
Ronan J. Kelly et al.
LANCET ONCOLOGY (2014)
A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries
Lianne Barnieh et al.
VALUE IN HEALTH (2014)
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data
Audrey Mauguen et al.
LANCET ONCOLOGY (2013)
Economic burden of cancer across the European Union: a population-based cost analysis
Ramon Luengo-Fernandez et al.
LANCET ONCOLOGY (2013)
The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada
Jean H. E. Yong et al.
PHARMACOECONOMICS (2013)
Delivering affordable cancer care in high-income countries
Richard Sullivan et al.
LANCET ONCOLOGY (2011)
End-of-Life Discussions, Goal Attainment, and Distress at the End of Life: Predictors and Outcomes of Receipt of Care Consistent With Preferences
Jennifer W. Mack et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009
Philip Savage
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?: Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
L Collette et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
